Success Metrics

Clinical Success Rate
100.0%

Based on 8 completed trials

Completion Rate
100%(8/8)
Active Trials
0(0%)
Results Posted
100%(8 trials)

Phase Distribution

Ph phase_3
8
100%

Phase Distribution

0

Early Stage

0

Mid Stage

8

Late Stage

Phase Distribution8 total trials
Phase 3Large-scale testing
8(100.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

8 of 8 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

8

all time

Status Distribution
Completed(8)

Detailed Status

Completed8

Development Timeline

Analytics

Development Status

Total Trials
8
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 38 (100.0%)

Trials by Status

completed8100%

Recent Activity

0 active trials
Showing 5 of 8
completedphase_3

Immunogenicity Study of the Japanese Encephalitis Vaccine IC51

NCT00604708
completedphase_3

Comparison of Three Batches of the Japanese Encephalitis Vaccine IC51

NCT00594958
completedphase_3

Immunogenicity and Safety of the Japanese Encephalitis Vaccine IC51 (IXIARO®, JESPECT®) in a Pediatric Population in Non-endemic Countries

NCT01047839
completedphase_3

Immunogenicity of a Commercial Batch of JEV IC51 up to 24 Months Post Filling

NCT00776230
completedphase_3

Effect of a Booster Dose of the Japanese Encephalitis Vaccine IC51

NCT00595309
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT00604708Phase 3

Immunogenicity Study of the Japanese Encephalitis Vaccine IC51

Completed
NCT00594958Phase 3

Comparison of Three Batches of the Japanese Encephalitis Vaccine IC51

Completed
NCT01047839Phase 3

Immunogenicity and Safety of the Japanese Encephalitis Vaccine IC51 (IXIARO®, JESPECT®) in a Pediatric Population in Non-endemic Countries

Completed
NCT00776230Phase 3

Immunogenicity of a Commercial Batch of JEV IC51 up to 24 Months Post Filling

Completed
NCT00595309Phase 3

Effect of a Booster Dose of the Japanese Encephalitis Vaccine IC51

Completed
NCT00596271Phase 3

Concomitant Vaccination With the Japanese Encephalitis Vaccine IC51 and HARVIX® 1440

Completed
NCT00595790Phase 3

Rapid Immunization Study of the Japanese Encephalitis Vaccine IC51

Completed
NCT00595270Phase 3

Long Term Persistence and Effect of a Booster Dose of the Japanese Encephalitis Vaccine IC51

Completed

All 8 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
8